---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045984"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:26:15.350626+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Esperion Q3 revenue $51.6M (+52% YoY); net loss narrows to $29.5M

## Summary
- Total revenue $51.6M (+52% YoY); U.S. net product revenue $31.1M (+53% YoY).
- Net loss $29.5M (EPS -$0.15) vs. $41.3M loss (-$0.37) in Q3 2023.
- Cash & equivalents $144.7M at Sep 30, up from $82.2M at Dec 31, 2023.
- Retail prescription equivalents +12% QoQ; Oct 2024 TRx +17% vs. first 4 weeks of Q3.
- European partner DSE royalty revenue $8.9M (+19% sequentially); Otsuka on track for Japan NDA filing by end 2024.

## SEC filing metadata
- accession: 0001628280-24-045984
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828024045984/0001628280-24-045984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828024045984/espr-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045984
- JSON: https://secwatch.observer/filing/0001628280-24-045984.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.